Novartis generic squares off with Glaxo's Advair in third EU country

Novartis' ($NVS) Advair knockoff is catching on in Europe. After Denmark approved AirFluSal Forspiro in December, the respiratory generic scored an approval in Germany and now has its third thumbs-up from Sweden. AirFluSal isn't directly substitutable for hard-to-copy Advair, which means it competes for market share like any other branded rival might. But it could still threaten a piece of Advair's $7.7-billion-a-year haul, which makes up nearly one-fifth of GlaxoSmithKline's ($GSK) total sales. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.